AAP
IMPL

Ardsley Advisory Partners’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Ardsley Advisory Partners’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-310,500
Closed -$3.78M – 169
2021
Q3 		$3.78M Buy
+310,500
New +$4.51M 0.58% 38

Other funds holding IMPL

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $375M AUM 72.65% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ardsley Advisory Partners's IMPL Position: Q4 2021 in Review

Ardsley Advisory Partners sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q4 2021, closing a stake of 310,500 shares — an estimated $3.78M sold.

Ardsley Advisory Partners first reported a position in IMPL in Q3 2021 and held it in 1 quarter. The position peaked at $3.78M in Q3 2021. 45 funds tracked by Wall St. Rank hold IMPL as of Q4 2021.

  • Ardsley Advisory Partners reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Ardsley Advisory Partners sold 310,500 Impel Pharmaceuticals Inc. Common Stock shares in Q4 2021, an estimated $3.78M.
  • Ardsley Advisory Partners first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Ardsley Advisory Partners's Impel Pharmaceuticals Inc. Common Stock position peaked at $3.78M in Q3 2021.
  • 45 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q4 2021.

Based on Ardsley Advisory Partners's 13F filing for Q4 2021, filed 14 Feb 2022.